GI/hepatology companies
27 listed GI/hepatology companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | TAK | ENTYVIO (vedolizumab) | Ulcerative colitis and Crohn's disease (IBD) | Q1 2027 — FDA PDUFA target action date (NDA under Priority Review) |
| Madrigal Pharmaceuticals, Inc. | MDGL | Rezdiffra (resmetirom) | noncirrhotic MASH with moderate to advanced liver fibrosis | 2027 — MAESTRO-NASH OUTCOMES results |
| Abivax S.A. | ABVX | obefazimod | moderately to severely active ulcerative colitis | 2026 — selection of follow-on compound |
| Mirum Pharmaceuticals, Inc. | MIRM | LIVMARLI (maralixibat) | Cholestatic pruritus in Alagille syndrome and PFIC | Q1 2027 — PBC topline data |
| Bausch Health Companies Inc. | BHC | Xifaxan (marketed Salix portfolio) | IBS-D; reduction in risk of overt hepatic encephalopathy recurrence; travelers' diarrhea | H1 2027 — FDA approval anticipated following submitted NDA (Phase 3 met all endpoints) |
| Inventiva S.A. | IVA | lanifibranor | MASH (metabolic dysfunction-associated steatohepatitis) | — |
| Ardelyx, Inc. | ARDX | tenapanor (IBSRELA) in chronic idiopathic constipation (ACCEL) | chronic idiopathic constipation (CIC) | 2026 — Complete enrollment in Phase 3 ACCEL |
| Sagimet Biosciences Inc. | SGMT | denifanstat (TVB-2640) | MASH (also acne and select cancers) | 2026 — Sagimet plans to initiate TVB-3567 Phase 2 clinical trial in moderate to severe acne patients before the end of 2026. |
| Gyre Therapeutics, Inc. | GYRE | F351 (hydronidone) | Chronic hepatitis B-associated liver fibrosis (PRC); MASH-associated liver fibrosis (US, pre-Phase 2) | 2026 — NMPA IND submission |
| Ironwood Pharmaceuticals Inc | IRWD | apraglutide | Short bowel syndrome dependent on parenteral support | — |
| Phathom Pharmaceuticals, Inc. | PHAT | VOQUEZNA (vonoprazan) | Erosive GERD, Non-Erosive GERD heartburn, H. pylori infection | Q4 2026 — Topline results from 12-week blinded treatment portion of Phase 2 EoE trial |
| Eupraxia Pharmaceuticals Inc. | EPRX | EP-104GI | Eosinophilic esophagitis (EoE) | December 2026 — Interim analysis of Phase 2b portion of RESOLVE (first 60 patients at 6 months) |
| AgomAb Therapeutics | AGMB | Ontunisertib (AGMB-129) | Fibrostenosing Crohn's disease | — |
| Altimmune, Inc. | ALT | pemvidutide | MASH | 2029 — 52-week PERFORMA Phase 3 readout |
| Galectin Therapeutics Inc | GALT | belapectin (GR-MD-02) | NASH cirrhosis / portal hypertension | — |
| Palisade Bio, Inc. | PALI | PALI-2108 | ulcerative colitis (UC) and Crohn's disease (incl. fibrostenotic Crohn's, FSCD) | H2 2026 — Initiate patient enrollment (first patient) |
| ProQR Therapeutics N.V. | PRQR | AX-0810 | cholestatic diseases (NTCP target) | — |
| Lucid Diagnostics Inc. | LUCD | EsoGuard Esophageal DNA Test with EsoCheck cell collection device | Early detection of Barrett's esophagus / esophageal precancer in at-risk GERD patients | — |
| Equillium, Inc. | EQ | EQ504 | ulcerative colitis and other GI diseases (inflammatory lung diseases as expansion) | Q4 2026 — Initiate Phase 1 placebo-controlled proof-of-mechanism study |
| PAVmed Inc. | PAVM | EsoGuard Esophageal DNA Test with EsoCheck Esophageal Cell Collection Device (via Lucid Diagnostics) | Early detection of Barrett's esophagus and esophageal adenocarcinoma in at-risk GERD patients | — |
| Jaguar Health, Inc. | JAGX | Mytesi (crofelemer 125 mg delayed-release tablets) | Symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy | H2 2026 — Submit final clinical study report to FDA |
| Tvardi Therapeutics, Inc. | TVRD | TTI-109 | Ulcerative colitis | Q4 2026 — Topline data from REVERT LIVER CANCER Phase 1b/2 clinical trial |
| Adial Pharmaceuticals, Inc. | ADIL | AT177 | ulcerative colitis | Q2 2027 — IND filing |
| CalciMedica, Inc. | CALC | Auxora (zegocractin) | acute pancreatitis (with SIRS); also AKI with AHRF | 2027 — Phase 1b proof-of-concept data in PAH |
| Chemomab Therapeutics Ltd. | CMMB | nebokitug | primary sclerosing cholangitis (PSC) | 2027 — Chemomab must initiate a Phase 2 trial of CM-101 within 12 months following FDA acceptance of an IND. |
| Curanex Pharmaceuticals Inc | CURX | Phyto-N | Ulcerative colitis (lead); also atopic dermatitis, rheumatoid arthritis, gout, diabetic foot, cancer cachexia | October 2026 — Pre-IND meeting with FDA |
| RedHill Biopharma Ltd. | RDHL | Talicia (omeprazole, amoxicillin, rifabutin) | H. pylori infection | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.